DNTH
NasdaqDianthus Therapeutics, Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$1.5M
2021
$6.4M
2022
$2.8M
2023
$6.2M
2024
$2.0M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$2.0M
Net Income$-162.3M
Gross Profit—
Oper Income$-177.9M
EPS (dil)$-4.20
Rev/sh$0.04
FCF/sh$-2.37
Book/sh$9.03
Gross M—
Oper M-8739.3%
Profit M-7973.3%
FCF M-6354.3%
ROE-32.9%
ROA-30.6%
ROIC-40.2%
R&D/Rev7153.1%
Rev Y/Y-67.3%
Rev 3Y CAGR-31.8%
EPS Y/Y-64.7%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh$0.00
Shs Chg Y/Y+15.9%
Current Ratio13.32
Quick Ratio—
Debt/Eq—
Int Coverage-1091.6×
Net Debt—
Total Debt—
Cash & Eq$51.3M
Total Assets$530.9M
Oper CF$-129.1M
Capex$314,000
Free CF$-129.4M
Buybacks—
Equity$493.4M
Liabilities$37.5M
Shs Outstand0.05B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-13.1M | $-29.7M | $-48.2M | $-101.9M | $-177.9M |
| Net Income | $-13.1M | $-28.5M | $-43.6M | $-85.0M | $-162.3M |
| Diluted EPS | $-15.01 | $-32.57 | $-8.45 | $-2.55 | $-4.20 |
| Operating Cash Flow | $-9.9M | $-29.1M | $-36.9M | $-78.2M | $-129.1M |
| Free Cash Flow | $-11.2M | $-29.4M | — | — | — |
COMMUNITY · $DNTH0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.